These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20120898)

  • 21. A cost-effectiveness comparison of embryo donation with oocyte donation.
    Finger R; Sommerfelt C; Freeman M; Wilson CK; Wade A; Daly D
    Fertil Steril; 2010 Feb; 93(2):379-81. PubMed ID: 19406398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Great Recession, insurance mandates, and the use of in vitro fertilization services in the United States.
    Kiatpongsan S; Huckman RS; Hornstein MD
    Fertil Steril; 2015 Feb; 103(2):448-54. PubMed ID: 25497450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The diversity of regulation and public financing of IVF in Europe and its impact on utilization.
    Berg Brigham K; Cadier B; Chevreul K
    Hum Reprod; 2013 Mar; 28(3):666-75. PubMed ID: 23223400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Socioeconomic approach to the practice of in vitro fertilization in the Brittany region in 1993].
    Poulain P; Le Lannou D; Le Martelot MT; Vialard J; Chevalier R; Corvez A; Keraudren B; Taillanter L; Giraud JR
    Contracept Fertil Sex; 1995 Apr; 23(4):261-6. PubMed ID: 7757134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is assisted reproduction the optimal treatment for varicocele-associated male infertility? A cost-effectiveness analysis.
    Schlegel PN
    Urology; 1997 Jan; 49(1):83-90. PubMed ID: 9000191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uninsured status and out-of-pocket costs at midlife.
    Johnson RW; Crystal S
    Health Serv Res; 2000 Dec; 35(5 Pt 1):911-32. PubMed ID: 11130804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health Care Access, Costs, and Treatment Dynamics: Evidence from In Vitro Fertilization.
    Hamilton BH; Jungheim E; McManus B; Pantano J
    Am Econ Rev; 2018 Dec; 108(12):3725-77. PubMed ID: 30497124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gamete intrafallopian transfer. A cost-effective alternative to donor oocyte in vitro fertilization in women aged 40-42 years.
    Silva PD; Olson KL; Meisch JK; Silva DE
    J Reprod Med; 1998 Dec; 43(12):1019-22. PubMed ID: 9883404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Health economic consequences of the choice of follicle stimulating hormone alternatives in IVF treatment].
    Poulsen PB; Højgaard A; Quartarolo JP
    Ugeskr Laeger; 2007 Apr; 169(14):1313-7. PubMed ID: 17437694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost of transferring one through five embryos per in vitro fertilization cycle from various payor perspectives.
    Little SE; Ratcliffe J; Caughey AB
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):593-601. PubMed ID: 16946220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insurance mandates and trends in infertility treatments.
    Henne MB; Bundorf MK
    Fertil Steril; 2008 Jan; 89(1):66-73. PubMed ID: 17482603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Publication of the results in all Dutch centers for in vitro fertilization: an important step towards an improvement in the effectiveness of the treatment].
    Fauser BC
    Ned Tijdschr Geneeskd; 2002 Dec; 146(49):2335-8. PubMed ID: 12510394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The medical expenditure panel survey: a national information resource to support healthcare cost research and inform policy and practice.
    Cohen JW; Cohen SB; Banthin JS
    Med Care; 2009 Jul; 47(7 Suppl 1):S44-50. PubMed ID: 19536015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [In vitro fertilization in France: economic aspects and influence of the gonadotropin choice (urinary vs. recombinant) on cost].
    de Mouzon J; Allavena E; Schmitt C; Frappé M
    Gynecol Obstet Fertil; 2004 Jun; 32(6):508-18. PubMed ID: 15217566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of a mild compared with a standard strategy for IVF: a randomized comparison using cumulative term live birth as the primary endpoint.
    Polinder S; Heijnen EM; Macklon NS; Habbema JD; Fauser BJ; Eijkemans MJ
    Hum Reprod; 2008 Feb; 23(2):316-23. PubMed ID: 18033807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary therapy for tubal disease: surgery versus IVF.
    Gocial B
    Int J Fertil Menopausal Stud; 1995; 40(6):297-302. PubMed ID: 8748918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of the costs, cost-effectiveness and third-party charges of bone marrow transplantation.
    Westerman IL; Bennett CL
    Stem Cells; 1996 May; 14(3):312-9. PubMed ID: 8724697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insurance coverage and in vitro fertilization outcomes: a U.S. perspective.
    Martin JR; Bromer JG; Sakkas D; Patrizio P
    Fertil Steril; 2011 Mar; 95(3):964-9. PubMed ID: 20688327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lapses in Medicaid coverage: impact on cost and utilization among individuals with diabetes enrolled in Medicaid.
    Hall AG; Harman JS; Zhang J
    Med Care; 2008 Dec; 46(12):1219-25. PubMed ID: 19300311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.